Cel Sci Corporation (CVM)

[steve2150]

This from March 13, 2014 from Seeking Alpha, way before the 25 for 1 R/S- $1.30 per share
Multikine showed very impressive tumor shrinkage, with 2 patients showing tumor elimination, in a Phase II Head and Neck Cancer Trial.

Current Phase III progress appears to be positive with final results due Dec 2017.

Multikine could be a blockbuster drug for Cel-Sci.

At 70M market value Cel-Sci is significantly undervalued, compared to their peers.

Cel-Sci (NYSEMKT:CVM) stock has seen significant appreciation since its low of $0.53 on Dec 19, 2013. The share value now sits around $1.30, which is almost a 130% gain in a little over 2 months. What is causing this? Cel-Sci could be onto a major cancer breakthrough stemming from a common sense method of treatment.